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B7-H3 is one of the most recently identiﬁed members of the B7/CD28 superfamily of costimulatory molecules serving as an
accessory modulator of T-cell response. Recently, B7-H3 expression has been reported in several human cancers indicating an
additional function of B7-H3 as a regulator of antitumor immunity. However, its precise physiologic role is still elusive, because
both stimulatory and inhibitory capacities have been demonstrated. This paper summarizes the available data on B7-H3 in the
regulation of T-cell response focusing on its potential role in antitumor immunity.
1.Introduction
T lymphocytes of the adaptive immune system are able to
recognize and speciﬁcally respond to an incredible variety
of foreign and native antigens. To ensure an appropriate T-
cell response, which is essential to eradicate pathogens and
to maintain self-tolerance, T-cell activation is ﬁnely tuned by
twoindependentsignalingpathways.Theﬁrstsignalrequires
recognition of the antigen-bearing major histocompatibility
complex (MHC) on the surface of antigen-presenting cells
(APCs) by the corresponding antigen-speciﬁc T-cell receptor
(TCR) on T-cells. The second signal, which is antigen
independent, is delivered by costimulatory molecules of
the B7/CD28 family. B7-1/B7-2:CD28/CTLA-4 signaling
represents the best characterized costimulatory pathway [1].
EngagementofB7-1onAPCswithCD28onT-cellsenhances
T-cell proliferation and IL-2 production. In the absence of
this simultaneous costimulatory signal, ligation of the TCR
by an antigenic peptide results in T-cell dysfunction, intoler-
ance or anergy. Apart from stimulatory signals that augment
and sustain T-cell responses, costimulatory pathways also
deliver inhibitory signals that downregulate or terminate T-
cell responses [2]. Binding of CTLA-4 to B7-1 and/or B7-2
inhibits IL-2 synthesis and progression through the cell cycle
leading to the termination of T-cell response. Within the
past two decades, new costimulatory ligands and receptors
havebeenidentiﬁed,includingB7-H1(programmeddeath-1
ligand-1), B7-DC (programmed death-1 ligand-2), PD-
1 (programmed death-1), ICOS (inducible costimulator),
ICOSL (ICOS-ligand), BTLA (B and T lymphocyte attenu-
ator), B7-H3, and B7-H4 [3].
Recently, these previously identiﬁed B7 homologues have
been implicated as potential regulators of antitumor immu-
nity. For example, aberrant B7-H1 expression by cancer
cells has been associated with adverse pathologic features
and poor outcome in diﬀerent human malignancies and has
thereforebeen postulated as a potential mechanism by which
malignant tumors may evade host immune response [4–8].
Takingadvantageofmanipulationofcostimulatorysignaling
bycancercellsiscomprehensibleasT-cellsplayanimportant
roleinantitumorimmunity.Undernormalconditions,APCs
that scavenge tumor cell debris and migrate to lymphoid
t i s s u e sc a ni n t e r a c tw i t hC D 4 + and CD8+ T-cells to induce
activation of T-cells capable of recognizing tumor-speciﬁc or
tumor-associated antigens. Thus, downregulation of tumor-
speciﬁc T-cell responses by abusing inhibitory signaling
pathways with induction of T-cell anergy or apoptosis
through aberrant tumor B7-H1 expression may represent
a possible immune escape mechanism. Hence, immune-
based therapies which eliminate inhibitory T-cell signaling
may represent a potent new approach for the treatment of
human malignancies. Indeed, several phase I/II trials using
humanized monoclonal antibodies (mAbs) to block CTLA-4
signaling have shown promising results in diﬀerent human2 Clinical and Developmental Immunology
cancers [9–12]. These studies provide evidence that treat-
ment with anti-CTLA-4 mAbs is generally well tolerated and
capable of inducing objective tumor responses in patients
with prostate cancer, renal cell carcinoma, melanoma, and
lymphoma [13–17].
B7-H3 is another recently identiﬁed costimulatory
molecule that has been implicated as a potential regulator
of antitumor response. However, its role in the regulation
of T-cell response and in antitumor immunity remains
controversial. This paper summarizes the existing data on
the immunological function of B7-H3 and focuses on the
potential role of B7-H3 in antitumor immunity.
2. B7-H3
2.1. Structure and Expression Pattern. B7-H3, identiﬁed in
2001, is a type I transmembrane protein that shares 20%–
27%aminoacididentity withotherB7familymembers[18].
AmongtheB7familymembers,B7-H3isthemostconserved
one with ∼88% amino acid identity between mice and
humans. While murine B7-H3 consists of a single extracel-
lular variable-type immunoglobulin (Ig)V-IgC domain and
a signature intracellular domain (2Ig B7-H3), human B7-H3
possesses an additional isoform, the so-called 4Ig B7-H3 that
contains a nearly exact tandem duplication of the IgV-IgC
domain [19, 20]. The 4Ig transcript is the dominant form in
human tissues. So far, only one potential receptor of murine
B7-H3 called triggering receptor expressed on myeloid cells
(TREM-) like transcript 2 (TLT-2) has been identiﬁed.
TLT-2 belongs to the TREM receptor family [21]. These
r e c e p t o r sf u n c t i o na sm o d u l a t o r so fc e l l u l a rr e s p o n s e sa n d
play important roles in both innate and adaptive immunities
[22]. TLT-2 protein expression has been shown on CD8+
T-cells constitutively and is induced on activated CD4+ T-
cells. Hashiguchi et al. recently found that binding of murine
B7-H3 to TLT-2 especially on CD8+ T-cells enhances T-cell
eﬀectorfunctionssuchasproliferation,cytokineproduction,
and cytotoxicity. Blockade of the TLT-2:B7-H3 pathway by
mAbs against B7-H3 or TLT-2 eﬀectively inhibited both the
induction and eﬀector phases of the contact hypersensitivity
responses. Although these in vitro data investigating the
interaction of murine B7-H3 with TLT-2 suggest that TLT-
2 might function as a receptor for B7-H3, Leitner and
colleagues did not ﬁnd evidence for such an interaction in
both mice and humans [23]. As an accessory costimulatory
molecule, B7-H3 protein is not constitutively expressed
on T-cells, natural killer (NK) cells, and APCs, but its
expression can be induced on these cell types. In contrast
to B7-1 and B7-2 whose expressions are mainly limited
t oi m m u n ec e l l ss u c ha sA P C s ,B 7 - H 3p r o t e i ni sf o u n d
on osteoblasts, ﬁbroblasts, ﬁbroblast-like synoviocytes, and
epithelial cells as well as in human liver, lung, bladder, testis,
prostate, breast, placenta, and lymphoid organs. This broad
expression pattern suggests more diverse immunological and
probably nonimmunological functions of B7-H3, especially
in peripheral tissues. Recently, B7-H3 expression has also
beenfoundinavarietyofdiﬀerenthumancancers,including
prostate cancer, clear cell renal cell carcinoma (ccRCC),
non-small-cell lung cancer (NSCLC), pancreatic cancer,
gastric cancer, ovarian cancer, colorectal cancer (CRC) and
urothelial cell carcinoma [24–31]. Although these ﬁndings
suggest a possible involvement of B7-H3 in the regulation of
antitumor immunity, its exact role remains far from clear,
because both stimulatory and inhibitory properties have
been identiﬁed and both beneﬁcial as well as adverse eﬀects
of B7-H3 expression in cancers have been reported.
2.2. Functional Studies. Initial work on the functional prop-
erties of B7-H3 showed a stimulatory eﬀect of human B7-H3
on T-cells. In vitro, B7-H3 was able to increase proliferation
of both CD4+ and CD8+ T-cells, enhance the induction of
cytotoxic T lymphocytes (CTLs), and selectively stimulate
interferon-gamma (IFN-γ) production in the presence of
anti-CD3 Abs to mimic the TCR signal [18]. By contrast,
inclusion of antisense B7-H3 oligonucleotides decreased
the expression of B7-H3 on dendritic cells (DCs) and
inhibited IFN-γ production by DC-stimulated allogeneic T-
cells. Further functional data in support of a stimulatory
eﬀect of B7-H3 come from several in vivo studies. Car-
diac allografts in treated B7-H3–/– mice showed markedly
decreased productions of key cytokine, chemokine, and
chemokine receptor mRNA transcripts as compared to wild-
type controls [32]. Moreover, the incidence of chronic
r e j e c t i o ni nt w od i ﬀerent cardiac allograft models was
also inhibited in B7-H3–/– mice as compared to wild-
type recipients. In a mouse model of allergic asthma,
administration of anti-B7-H3 mAbs signiﬁcantly reduced
airway hyperactivity and resulted in decreased production
of Th2 cytokines (interleukin-4 (IL-4), IL-5, and IL-13) as
compared with control IgG-treated mice [33]. Furthermore,
transfection of B7-H3 into mouse P815 tumor cells that were
inoculated into syngeneic DBA/2 mice resulted in complete
tumor regression of about one-half of the tumors and
ampliﬁcation of tumor-speciﬁc CD8+ CTL response [34].
The authors concluded that B7-H3 transfection enhanced
the immunogenicity of the inoculated tumor cells. Similarly,
injection of a mouse B7-H3 pcDNA3 expression plasmid
into EL-4 lymphomas led to complete regression of 50%
of tumors or otherwise signiﬁcantly slowed tumor growth
[35]. B7-H3-driven antitumor immunity was mediated
by CD8+ T-cells and NK cells. In an orthotopic murine
colon cancer model, treatment by intratumoral injection of
an adenovirus expressing mouse B7-H3 (Ad-B7-H3-GFP)
resulted in a reduction of tumor size compared to control
animals [36]. In addition, the occurrence of secondary
metastasis was signiﬁcantly reduced. Ad-B7-H3-GFP-treated
animals showed signiﬁcantly higher frequencies of tumor-
speciﬁc IFN-γ producing CD8+ T-cells. Based on these
mouse cancer models, tumor-associated B7-H3 seems to
preferentially regulate CD4-independent induction of CD8+
CTL responses. Further lines of evidence for a stimulatory
eﬀect of B7-H3 come from a murine hepatocellular carci-
noma model. Intratumoral injection of B7-H3-expressing
plasmidsfollowedbyvasostatin-expressingplasmidinjection
24 hours later resulted in a complete eradication of subcu-
taneous H22 tumors [37]. Interestingly, neither B7-H3 norClinical and Developmental Immunology 3
vasostatin monotherapy was eﬀective. In contrast to these
ﬁndings,whichstronglysuggestastimulatoryeﬀectofB7-H3
on T-cell responses and antitumor immunity, other groups
haveproposedoppositefunctionsforB7-H3.Inmice,B7-H3
protein inhibited T-cell activation and eﬀector cytokine pro-
duction [38]. Furthermore, an antagonistic mAb to B7-H3
enhanced T-cell proliferation in vitro and led to exacerbated
experimental autoimmune encephalomyelitis (EAE) in vivo
[39]. In B7-H3–/– mice, Th1-mediated hypersensitivity and
onset of EAE were promoted, and treatment with a blocking
anti-B7-H3 mAb exacerbated EAE [38]. In a murine model
of experimental allergic conjunctivitis (EC), administration
of anti-B7-H3 mAbs during the induction phase augmented
the severity of Th2-mediated EC [40]. In a diﬀerent study,
DC-associated B7-H3 induced by CD4+CD25+ regulatory
T-cells (Tregs) impaired T-cell stimulatory function in vivo
[41]. Accordingly, B7-H3–/– mice developed EAE earlier as
wild-type littermates. Moreover, B7-H3–/– mice developed
more severe airway inﬂammation under conditions in which
T helper cells diﬀerentiated toward Th1 rather than Th2. In a
diﬀerent in vitro study, B7-H3 inhibited T-cell proliferation
of both CD4+ and CD8+ T-cells mediated by Ab to T-cell
receptor or allogeneic APCs [38].
2.3. Retrospective Analyses. In accordance to its inconsistent
immunologic function regarding the regulation of T-cell
responses which was demonstrated by several in vitro and in
vivo studies, the role of B7-H3 in human cancer remains far
from clear.
Data in support of a possible stimulatory function
of B7-H3 in T-cell and antitumor responses come from
retrospective analyses in diﬀerent human cancers. In gastric
cancer, 58.8% of gastric cancer cells in a series of 102 patients
have been shown to express B7-H3 in the cell membrane
and cytoplasm [26]. Tumor B7-H3 expression positively
correlated with survival time, inﬁltration depth, and tissue
type. In pancreatic cancer, high tumor B7-H3 expression
by cancer cells in 68 examined patients was signiﬁcantly
associated with prolonged patient survival after surgical
resection and signiﬁcantly correlated with the number of
tumor-inﬁltrating CD8+ T-cells [25].
However, several studies in other human cancers cor-
relating tumor B7-H3 expression with clinicopathological
features do not concur with these ﬁndings. Tumor B7-H3
expression in 70 patients with NSCLC inversely correlated
with the number of tumor-inﬁltrating lymphocytes (TILs)
andsigniﬁcantlycorrelatedwithlymphnodemetastasis[24].
In a separate study, the level of circulating soluble B7-
H3 (sB7-H3) in patients with NSCLC was associated with
higher tumor stage, tumor size, nodal metastasis, and distant
metastasis [42]. In ccRCC, 17.4% of tumor cells and 95.1%
of tumor vasculature in 743 examined patients expressed
B7-H3. B7-H3 expression in either tumor cells or tumor
vasculature was found to signiﬁcantly associate with an
increased risk of death from ccRCC [28]. In another clinical
study, B7-H3 was found to be uniformly and aberrantly
expressed in adenocarcinomas of the prostate (n = 338).
Marked B7-H3 intensity, which was found in approximately
20% of the examined specimens, was associated with a
>4-fold increased risk of cancer progression after surgery
[31]. Similar results were shown in another study that
investigated B7-H3 expression in 823 patients with prostate
cancer. Tumor B7-H3 expression was found in 93% of
patients treated with radical prostatectomy [43]. Strong B7-
H3 expression in the resected specimens correlated with
disease spread and poor outcome. In CRC, strong B7-H3
expression could be observed in 54.3% of 102 CRC patients.
Higher B7-H3 expression positively correlated with a more
advanced tumor grade and negatively correlated with the
intensity of TILs [29]. Most recently, B7-H3 was found to
be expressed in 93% of 103 examined ovarian borderline
tumors and carcinomas. B7-H3 was also expressed in the
endothelium of tumor-associated vasculature in 44% of
patients.CarcinomaswithB7-H3-positivetumorvasculature
were associated with a signiﬁcantly shorter survival time and
a higher incidence of recurrence [27]. All relevant studies
regarding the clinical signiﬁcance of B7-H3 in human cancer
are summarized in Table 1 [24–31, 43–47].
2.4. Reasons for the Contrasting Immunomodulatory Eﬀects
of B7-H3. Based on the latter experimental and clinical
data, the role of B7-H3 in human cancer remains unclear.
Several explanations for the seemingly conﬂicting data exist,
including the possible existence of additional receptors
for B7-H3. So far, only TLT-2 has been identiﬁed as a
potential receptor for B7-H3 that seems to enhance T-cell
eﬀector function in mice [21]. However, B7-H3 might use
another receptor besides TLT-2 for its inhibitory function.
Furthermore,ithastobeconsideredthatmostoftheexisting
functional studies have been performed in mouse models
and that data regarding the immunomodulatory eﬀects of
B7-H3 from these murine studies might not be transferable
into humans. Evidence for diﬀerences between mouse and
human B7-H3 includes the existence of varying isoforms.
In mice, the predominant isoform of B7-H3 consists of a
classical single extracellular IgV-IgC domain (2Ig B7-H3)
whereas the predominant isoform in humans consists of a
dual IgV-IgC domain (4Ig B7-H3). It is also conceivable
that other additional isoforms may exist. Another possible
explanation for the inconclusive data on the functional role
of B7-H3 in antitumor response comprises the level of B7-
H3 expression on cancer cells that may be of relevance for
the induction of diﬀerent immunological functions. Based
on its expression level, B7-H3 may interact with diﬀerent
aﬃnities for several existing receptors and may therefore
exert diﬀerent functions. A similar functional discrepancy
regarding the expression levels of a costimulatory molecule
incancerhasbeenshownforB7-1[48].Becauseofinhibitory
eﬀects on immune response, low B7-1 expression on murine
colon carcinoma cell lines has been implicated as a possible
immune-escape mechanism for tumor cells, presumably
through binding of the inhibitory T-cell receptor CTLA-4.
By contrast, artiﬁcially enforced expression of B7-1 on these
tumor cells resulted in a strong increase of immunogenicity.
The authors of this study concluded that the diﬀerent eﬀect
of B7-1 may be explained by the noticeable higher aﬃnity of4 Clinical and Developmental Immunology
Table 1: Relevant clinical studies investigating the relationship between B7-H3 expression in human cancer tissues with clinicopathological
features.
Author Journal Year Type of
malignancy
Number of
patients
Positive
tumor-
associated
Correlation with clinicopathologic features
B7-H3
expression Favorable Adverse
Sun et al.
[29]
Cancer
Immunol
Immunother
2010 Colorectal
cancer 102 87.3% — Higher tumor B7-H3 correlated
with a more advanced tumor grade
Zang et al.
[27]
Mod Pathol 2010 Ovarian
carcinoma 103
93% of tumor
cells —
Signiﬁcant shorter survival time and
higher incidence of recurrence for
patients with positive B7-H3 tumor
vasculature
44% of tumor
vasculature
Parker et
al. [46]
Int J Radiat
Oncol Biol Phys 2010 Recurrent
prostate cancer 148 100% —
Increased risk of biochemical
recurrence for patients with
moderate and marked B7-H3
staining
Loos et al.
[25] BMC Cancer 2009 Pancreatic
cancer 68 88.2%
high tumor
B7-H3
expression was
associated with
signiﬁcantly
better
postoperative
prognosis
—
Boorjian
et al. [44] Urology 2009
Renal angiomy-
olipoma/
pulmonary
lymphangio-
leiomyomatosis
110/7 100% and
2.7% ——
Yamato
et al. [47] Br J Cancer 2009 Pancreatic
cancer 59 93.2% —
Strong tumor B7-H3 expression was
signiﬁcantly associated with lymph
node metastasis and advanced
pathological stage
Crispen
et al. [28]
Clin Cancer Res 2008 ccRCC 743
17% of tumor
cells —
Either tumor cell or diﬀuse
tumor vasculature B7-H3
expression was signiﬁcantly
associated with an increased risk
of death from ccRCC
95% of tumor
vasculature
Boorjian
et al. [30] Clin Cancer Res 2008 Urothelial cell
carcinoma 318 70.7% — —
Greorio
et al. [45] Histopathology 2008 Neuroblastoma 53 74% —
High tumor B7-H3 expression was
associated with a worse event-free
survival
Zang et al.
[43] PNAS 2007 Prostate cancer 823 93% —
Patients with strong tumor B7-H3
expression were at signiﬁcantly
increased risk of clinical cancer
recurrence and cancer-speciﬁc death
Roth et al.
[31] Cancer Res 2007 Prostate cancer 338 100% —
(1) Increasing levels of tumor
B7-H3 intensity correlated with
worsening clinicopathologic
features, including tumor volume,
extraprostatic extension, higher
Gleason score, seminal vesicle
involvement, surgical margins
(2) Marked tumor B7-H3 intensity
was signiﬁcantly associated with
cancer progressionClinical and Developmental Immunology 5
Table 1: Continued.
Author Journal Year Type of
malignancy
Number of
patients
Positive
tumor-
associated
Correlation with clinicopathologic features
B7-H3
expression Favorable Adverse
Sun et al.
[24] Lung Cancer 2006 NSCLC 70 37.1% —
High tumor B7-H3 expression was
signiﬁcantly more common in cases
with lymph node metastasis
Wu et al.
[26]
World J
Gastroenterol 2006 Gastric cancer 102 58.8%
Positive tumor
B7-H3
expression was
signiﬁcantly
associated with
better
postoperative
survival
—
B7-1 for CTLA-4 which has been shown to be 100- to 1,000-
fold higher than for CD28. Apart from the possible existence
of additional B7-H3 receptors, the deﬁnition of positive B7-
H3 expression and B7-H3 expression levels in the available
studies was not standardized. In the study analyzing the role
of B7-H3 in human gastric cancer, specimens were scored
as B7-H3-expressing tumors when more than 20% of tumor
cells stained positive for B7-H3 [26]. Sun et al. deﬁned low
tumor-B7-H3 expression in NSCLC when less than 10% of
tumors expressed B7-H3 [24]. In this study, 37.1% of the
examined specimens expressed B7-H3. In ccRCC, tumors
with less than 10% of cells stained positive were scored
as having negative B7-H3 expression. 17% of specimens
revealed positive tumor cell B7-H3 expression [28]. Zang
et al. did not deﬁne the diﬀerence between high or low
tumor B7-H3 expression in prostate cancer at all [43]. In
none of these studies, B7-H3 staining intensity was not
taken into account. In our recent study, the most detailed
scoring system was used for expression analysis of B7-H3 in
pancreaticcancer.Scoresweregivenseparatelyforthestained
area and for the intensity of staining [25]. In addition to the
diﬀerent deﬁnitions of positive B7-H3 expression and B7-
H3 expression levels that were used in previous retrospective
studies, a possible inﬂuence of soluble forms of B7-H3 was
not examined. Based on a study analyzing sB7-H3 levels
in NSCLC that showed that the level of circulating sB7-H3
was associated with higher tumor stage, tumor size, nodal
metastasis, and distant metastasis, one could speculate that
sB7-H3 may also contribute to the modulation of immune
response [42]. Another possible reason may include the
expression of aberrant forms of B7-H3 on tumor cells which
cannot be diﬀerentiated by the existing antibodies.Yi and
Chen recently worried that many so-called “neutralizing
antibodies” may not be just blocking antibodies but have
other eﬀects such as triggering the B7-H3 signal [49].
Furthermore, genetic polymorphisms in B7-H3 may modify
T-cell responses in human cancers. Recent studies have
shown that polymorphisms in the inhibitory molecule
CTLA-4 alter cancer susceptibility through modiﬁcation of
T-cell response [50]. Finally, B7-H3 may also aﬀect other
immune cells than T-cells. In neuroblastoma, 4Ig-B7-H3
molecules expressed at the tumor cell surface have been
shown to exert a protective role from NK-mediated lysis
by interacting with a still undeﬁned inhibitory receptor
expressed on NK cells [19].
2.5. Therapeutic Potential of B7-H3. Immune-based thera-
pies which additionally stimulate T-cell activation or elim-
inate inhibitory T-cell signaling in order to enforce tumor-
reactive T-cell responses represent a potent new approach
for the treatment of human malignancies. Blockade of the
inhibitory receptor CTLA-4 by mAbs has been tested as a
single agent or in combinations in patients with advanced
cancer, including breast cancer, lymphoma, melanoma,
ovarian cancer, prostate cancer, and ccRCC [9, 15, 17, 51–
54]. Most trials have not only shown that anti-CTLA-4
mAb treatment is safe but also provide evidence for its
antitumor eﬀects. In unresectable advanced melanoma for
instance, durable tumor responses and disease control rates
have been observed. PD-1 is another inhibitory receptor
expressed on activated T-cells that may suppress antitu-
mor immunity. Therefore, single-agent anti-PD-1 blockade
has been tested in a Phase I trial of 39 patients with
advanced metastatic melanoma, CRC, NSCLC, castrate-
resistant prostate cancer, and ccRCC. Anti-PD-1 treatment
resulted in one durable complete response and two partial
responses [55].
Given its immunomodulatory capacities, B7-H3 may
alsorepresentanewtargetincancertreatment.Incontrastto
CTLA-4andPD-1,however,onehastotakeintoaccountthat
B7-H3 is more broadly expressed, especially in peripheral
healthy tissues. Therefore, blockade of B7-H3 by mAbs or
treatment with B7-H3 (i.e., by gene transfer) may be associ-
ated with severe adverse eﬀects. Furthermore, the functional
role of B7-H3 in antitumor immunity is not completely
understood, and controversies regarding its stimulatory and
inhibitory capacities remain to be elucidated.6 Clinical and Developmental Immunology
3. Conclusions
Within the past decade, new insights into immunomod-
ulatory capacities of costimulatory signaling in antitumor
response have opened the door for new potent approaches in
cancer therapy. Recent clinical Phase I/II trials have provided
solid evidence that treatment with anti-CTLA-4 mAbs is
capable of inducing objective antitumor responses. B7-H3,
a recently identiﬁed member of the B7/CD28 superfamily
of costimulatory molecules, has been shown to play an
important role in immune regulation. Although data on the
precise role of B7-H3 in the regulation of T-cell responses
and especially in antitumor immunity has yet to be eluci-
dated,B7-H3representsapromisingnewtargetforimmune-
based antitumor therapies. The previous identiﬁcation of
the costimulatory receptor TLT-2 is the ﬁrst signiﬁcant step
toward resolving the available conﬂicting data.
However, further work particularly concerned with the
identiﬁcation of inhibitory receptors for B7-H3 is ongoing.
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